- Home
- PRAX vs HBNB Comparison
PRAX vs HBNB Comparison
Compare PRAX & HBNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- HBNB
- Stock Information
- Founded
- PRAX 2015
- HBNB 2016
- Country
- PRAX United States
- HBNB Singapore
- Employees
- PRAX N/A
- HBNB N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- HBNB
- Sector
- PRAX Health Care
- HBNB
- Exchange
- PRAX Nasdaq
- HBNB NYSE
- Market Cap
- PRAX 950.8M
- HBNB 768.0M
- IPO Year
- PRAX 2020
- HBNB N/A
- Fundamental
- Price
- PRAX $59.22
- HBNB $2.47
- Analyst Decision
- PRAX Strong Buy
- HBNB
- Analyst Count
- PRAX 10
- HBNB 0
- Target Price
- PRAX $101.00
- HBNB N/A
- AVG Volume (30 Days)
- PRAX 399.5K
- HBNB 415.9K
- Earning Date
- PRAX 08-12-2025
- HBNB 01-01-0001
- Dividend Yield
- PRAX N/A
- HBNB N/A
- EPS Growth
- PRAX N/A
- HBNB N/A
- EPS
- PRAX N/A
- HBNB N/A
- Revenue
- PRAX $8,122,000.00
- HBNB N/A
- Revenue This Year
- PRAX N/A
- HBNB N/A
- Revenue Next Year
- PRAX $4,434.72
- HBNB N/A
- P/E Ratio
- PRAX N/A
- HBNB N/A
- Revenue Growth
- PRAX 270.02
- HBNB N/A
- 52 Week Low
- PRAX $26.70
- HBNB $2.02
- 52 Week High
- PRAX $91.83
- HBNB $19.28
- Technical
- Relative Strength Index (RSI)
- PRAX 78.36
- HBNB N/A
- Support Level
- PRAX $53.89
- HBNB N/A
- Resistance Level
- PRAX $59.10
- HBNB N/A
- Average True Range (ATR)
- PRAX 3.26
- HBNB 0.00
- MACD
- PRAX 0.59
- HBNB 0.00
- Stochastic Oscillator
- PRAX 88.19
- HBNB 0.00
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About HBNB HOTEL101 GLOBAL HLDGS CORP
Hotel101 Global Holdings Corp is an asset-light, prop-tech hospitality platform. The company generates revenue twice: first, in the form of upfront revenue from the sale of its standardized hotel units to real estate unit buyers, and second, in the form of recurring revenues from long-term contracts for the day-to-day management and operation of these hotel units enrolled on the Hotel101 platform.